Peer-reviewed veterinary case report
Canine papillomavirus diagnosis and vaccine updates
By Feng, Yuan et al.·Published in Virology journal·2025·Department of Pediatrics, China·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Canine papillomavirus: status of diagnostic methods and vaccine innovations.
- Species:
- dog
Plain-English summary
A dog with warts on its skin may have a viral infection called Canine Papillomavirus (CPV). While most cases are harmless, some strains can cause serious issues, especially in sick or older dogs. Early diagnosis is important, and while there are advanced tests available, they can be complicated and not always easy to access. Researchers are working on new vaccines to help protect dogs from this virus, but a commercially available vaccine is not yet on the market. Keeping your dog healthy and monitoring for any unusual growths is key.
People also search for: dog warts treatment · Canine Papillomavirus symptoms · dog skin growths · CPV vaccine for dogs · how to treat dog papillomas
Abstract
Canine Papillomavirus (CPV) is a prevalent viral infection in dogs, characterized by the formation of benign warts or papillomas on the skin and mucous membranes. While most CPV types result in non-malignant growths, certain strains, particularly in immunocompromised dogs (e.g., sick or elderly animals), can lead to malignant transformations. This highlights the need for early, accurate diagnosis, alongside preventive vaccination, to manage the disease effectively. Diagnostic methods leverage CPV's unique characteristics, including histopathology with hematoxylin and eosin (H&E) staining for assessing neoplastic tissue growth and cytopathy, molecular techniques like polymerase chain reaction (PCR), rolling circle amplification (RCA), DNA in situ hybridization (ISH), and next-generation sequencing (NGS) for detecting CPV genomic DNA, immunohistochemistry (IHC) and enzyme-linked immunosorbent assay (ELISA) for identifying viral antigen such as the L1 protein, as well as transmission electron microscopy (TEM) for visualizing viral particles in lesions. These approaches display appreciable sensitivity and specificity and are often utilized in CPV research, though they also have certain intrinsic limitations, such as accessibility, technical complexity. Advancements in CPV vaccine development, including inactivated, live-attenuated, DNA-based, and recombinant protein-based formulations, show promise in achieving effective protection. However, a commercially available vaccine has yet to be developed. Furthermore, challenges persist in developing convenient, cost-effective diagnostics suitable for diverse clinical applications and in formulating affordable, cross-protective vaccines. This review emphasizes the importance of continued innovation in CPV diagnostics and vaccine development to mitigate both benign and malignant papillomatosis, enhance disease prevention, and safeguard canine health.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40307903/